AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Kallikrein-2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P20151

UPID:

KLK2_HUMAN

Alternative names:

Glandular kallikrein-1; Tissue kallikrein-2

Alternative UPACC:

P20151; B4DU93; B4DUB0; F5H8L3; Q15946; Q9UJZ9

Background:

Kallikrein-2, also known as Glandular kallikrein-1 or Tissue kallikrein-2, plays a pivotal role in the kallikrein-kinin system. It is instrumental in cleaving Met-Lys and Arg-Ser bonds in kininogen, leading to the release of Lys-bradykinin. This process is crucial for regulating blood pressure, inflammation, and pain, showcasing the protein's significant impact on physiological processes.

Therapeutic significance:

Understanding the role of Kallikrein-2 could open doors to potential therapeutic strategies. Its involvement in critical physiological pathways highlights its potential as a target for developing treatments aimed at modulating blood pressure, inflammation, and pain management.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.